/HNSA.ST

HNSA.ST Stock - Hansa Biopharma AB (publ)

Q: What is the analyst price target for HNSA.ST?

Analyst price target information is not currently available for HNSA.ST.

Q: What is HNSA.ST's market cap?

Market capitalization information is not currently available for HNSA.ST.

Healthcare|Biotechnology|STO

$31.24+1.76%

+$0.54 (+1.76%) • Dec 23

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $34.36

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for HNSA.ST

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta1.82

52W High$42.98

52W Low$19.58

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	$171.32M	$134.09M	$154.53M	$33.88M	$6.10M
Gross Profit	$87.76M	$70.95M	$116.05M	$18.45M	$5.10M
Gross Margin	51.2%	52.9%	75.1%	54.5%	83.7%
Operating Income	$-637,878,000	$-788,496,000	$-576,120,000	$-539,580,000	$-425,077,000
Net Income	$-807,243,000	$-831,720,000	$-611,134,000	$-548,282,000	$-420,853,000
Net Margin	-471.2%	-620.3%	-395.5%	-1618.4%	-6901.5%
EPS	$-12.84	$-15.83	$-13.60	$-12.33	$-9.98

Company Overview

Hansa Biopharma AB (publ), a biopharmaceutical company, develops immunomodulatory treatments for enabling transplants and rare immunoglobulin G (IgG)-mediated autoimmune conditions, gene therapy, and cancer using its proprietary enzyme technology platform. The company's lead drug candidate is Imlifidase, an antibody cleaving enzyme therapy that is in phase 3 clinical trial for use in sensitized kidney transplantations patients, as well as for anti-GBM antibody disease; and phase 2 clinical trial for antibody-mediated kidney transplant rejection and Guillain Barré syndrome. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology; and Enzyme based antibody Enhancement (EnzE), which is cancer immunotherapy. The company has a preclinical research collaboration agreement with argenx BV to evaluate the therapeutic potential of combining the two companies' IgG-modulating technologies. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.

Visit Website

Earnings History & Surprises

HNSA.ST

Beat Rate

38%

Last 16 quarters

Avg Surprise

-24.5%

EPS vs Estimate

Beats / Misses

6/10

Last 12 quarters

Latest EPS

$-1.75

Q4 2025

EPS Surprise History

Q1 24

+37.4%

$-2.36vs$-3.77

Q2 24

-19.9%

$-4.15vs$-3.46

Q3 24

-18.7%

$-3.30vs$-2.78

Q4 24

+36.8%

$-1.53vs$-2.42

Q1 25

-121.7%

$-4.08vs$-1.84

Q2 25

+79.4%

$-0.55vs$-2.67

Q3 25

-50.4%

$-2.53vs$-1.68

Q4 25

+0.9%

$-1.75vs$-1.76

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2026	Apr 22, 2026	—	—	—	—
Q1 2026	Feb 11, 2026	$-1.76	—	—	—
Q4 2025	Oct 30, 2025	$-1.76	$-1.75	+0.9%	✓ BEAT
Q3 2025	Jul 17, 2025	$-1.68	$-2.53	-50.4%	✗ MISS
Q2 2025	Apr 24, 2025	$-2.67	$-0.55	+79.4%	✓ BEAT
Q1 2025	Feb 6, 2025	$-1.84	$-4.08	-121.7%	✗ MISS
Q4 2024	Oct 17, 2024	$-2.42	$-1.53	+36.8%	✓ BEAT
Q3 2024	Jul 18, 2024	$-2.78	$-3.30	-18.7%	✗ MISS
Q2 2024	Apr 18, 2024	$-3.46	$-4.15	-19.9%	✗ MISS
Q1 2024	Mar 4, 2024	$-3.77	$-2.36	+37.4%	✓ BEAT
Q4 2023	Oct 26, 2023	$-3.75	$-4.78	-27.5%	✗ MISS
Q3 2023	Jul 20, 2023	$-3.71	$-4.79	-29.1%	✗ MISS
Q2 2023	Apr 20, 2023	$-2.92	$-3.92	-34.4%	✗ MISS
Q1 2023	Feb 2, 2023	$-4.14	$-3.22	+22.1%	✓ BEAT
Q3 2022	Sep 30, 2022	$-1.90	$-3.45	-81.7%	✗ MISS
Q2 2022	Jun 30, 2022	$-1.88	$-3.82	-103.9%	✗ MISS
Q2 2022	Apr 21, 2022	$-3.61	$-3.11	+13.8%	✓ BEAT
Q1 2022	Feb 3, 2022	$-1.89	$-3.67	-94.9%	✗ MISS
Q4 2021	Oct 21, 2021	—	$-2.98	—	—
Q3 2021	Sep 30, 2021	—	$-3.34	—	—

Frequently Asked Questions about HNSA.ST

What is HNSA.ST's current stock price?

Hansa Biopharma AB (publ) (HNSA.ST) is currently trading at $31.24 per share. The stock has moved +1.76% today.

What is the analyst price target for HNSA.ST?

No analyst price targets are currently available for this stock.

What sector is Hansa Biopharma AB (publ) in?

Hansa Biopharma AB (publ) operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the STO exchange.

What is HNSA.ST's market cap?

Hansa Biopharma AB (publ) has a market capitalization of $2.65 billion, making it a mid-cap company.

Does HNSA.ST pay dividends?

No, Hansa Biopharma AB (publ) does not currently pay a dividend to shareholders.